Revolution Medicines (RVMD) Stock: Executive Sells $3.5M While Wall Street Upgrades to Strong-Buy

Quick Summary

Table of Contents

Anthony Mancini, Chief Global Commercialization Officer, offloaded 26,552 shares totaling approximately $3.5M on March 25 through a predetermined 10b5-1 trading arrangement
Shares started trading at $94.29, declining 1.3%, within its annual trading band of $29.17 to $124.49
On March 26, Truist Financial raised its rating to “strong-buy,” aligning with positive calls from Jefferies, Evercore, UBS, and Wedbush
Company insiders have divested roughly 149,592 shares (approximately $15M) over the previous three months, though institutional holders control 94.34% of shares
Fourth quarter 2025 earnings revealed a loss of $1.86 per share versus analyst expectations of -$1.56, primarily due to elevated R&D and administrative spending

Revolution Medicines (RVMD) stock began Wednesday’s session, March 26, at $94.29, representing a 1.3% decline from the previous close.

Revolution Medicines, Inc., RVMD

Company executive Anthony Mancini, serving as Chief Global Commercialization Officer, executed a sale of 26,552 shares on March 25, generating proceeds of roughly $3.5 million. The share prices during these transactions varied between $93.22 and $97.21.

These sales occurred through a Rule 10b5-1 trading arrangement that Mancini established on December 24, 2025. Such pre-established plans allow insiders to schedule stock sales in advance, reducing concerns that transactions reflect negative internal perspectives on company performance.

Concurrently, Mancini exercised stock options to purchase 37,450 shares at a strike price of $33.62 each, representing approximately $1.26 million in total value. Following these combined activities, his direct holdings comprise 54,400 shares plus an additional 54,400 restricted stock units.

Mancini’s transactions follow a broader pattern of insider activity. Mark A. Goldsmith, another company insider, disposed of 12,871 shares on March 17 at an average price of $99.48, generating proceeds exceeding $1.28 million. On the identical date, CFO Jack Anders sold 2,753 shares at the same price point, totaling approximately $274,000.

Collectively, company insiders have sold approximately 149,592 shares valued at $15 million during the past three-month period. Insiders currently maintain ownership of 8.20% of outstanding shares.

Truist Elevates Rating to Strong-Buy Territory

Notwithstanding the insider selling activity, Wall Street analysts maintain predominantly optimistic views. On March 26, Truist Financial elevated RVMD to “strong-buy” status.

Evercore issued an identical recommendation earlier on February 25. Jefferies launched coverage with a “buy” rating on March 16. UBS similarly initiated coverage with a “buy” designation on February 27.

The singular bearish voice belongs to Weiss Ratings, maintaining a “sell (d-)” stance. MarketBeat’s aggregated consensus reflects a “Buy” rating with a mean price objective of $78.94—considerably beneath current trading levels.

Individual analyst targets demonstrate greater optimism. Piper Sandler increased its forecast to $120 with an Overweight rating, Wells Fargo established a $144 target, and Needham positions its price objective at $145 alongside a Buy recommendation.

Institutional Capital Flows In Despite Earnings Shortfall

Regarding institutional investment activity, significant capital has entered the stock. Norges Bank established a fresh position valued at approximately $195.6 million during Q4. Avoro Capital initiated holdings worth roughly $172.8 million. UBS expanded its stake by 183.6% to 3,087,937 shares, representing nearly $246 million in value. Polar Capital amplified its position by 321.2%, currently maintaining over 2 million shares.

Institutional investment firms collectively control 94.34% of RVMD.

This optimistic institutional positioning persists despite Revolution Medicines missing Q4 2025 earnings projections. The biotech firm posted a loss of $1.86 per share, falling short of the consensus forecast of -$1.56 by $0.30. Management attributed the wider-than-anticipated loss to R&D investments and selling, general, and administrative costs exceeding expectations.

Revenue generation wasn’t problematic—the company concluded the quarter maintaining $2.03 billion in cash reserves and investment securities, partially attributable to a strategic partnership with Royalty Pharma. Wall Street analysts currently forecast a full-year loss of $3.49 per share for fiscal 2026.

RVMD’s 50-day moving average stands at $101.53, while its 200-day moving average registers at $78.24. The biotechnology company commands a market capitalization of $18.69 billion.

Over the trailing twelve months, RVMD has delivered impressive returns of 145%. During the most recent six-month period, shares have appreciated 112%.

✨ Limited Time Offer